These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25185168)

  • 21. Immunohistochemistry as a Practical Tool in Molecular Pathology.
    Sheffield BS
    Arch Pathol Lab Med; 2016 Aug; 140(8):766-9. PubMed ID: 27472235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycoconjugates from extracellular vesicles: Structures, functions and emerging potential as cancer biomarkers.
    Costa J
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):157-166. PubMed ID: 28347750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting.
    Giaginis C; Vgenopoulou S; Vielh P; Theocharis S
    Histol Histopathol; 2010 Mar; 25(3):351-70. PubMed ID: 20054807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.
    Robles AI; Olsen KS; Tsui DW; Georgoulias V; Creaney J; Dobra K; Vyberg M; Minato N; Anders RA; Børresen-Dale AL; Zhou J; Sætrom P; Nielsen BS; Kirschner MB; Krokan HE; Papadimitrakopoulou V; Tsamardinos I; Røe OD
    J Transl Med; 2016 Oct; 14(1):295. PubMed ID: 27756323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma.
    Roland CL; Boland GM; Demicco EG; Lusby K; Ingram D; May CD; Kivlin CM; Watson K; Al Sannaa GA; Wang WL; Ravi V; Pollock RE; Lev D; Cormier JN; Hunt KK; Feig BW; Lazar AJ; Torres KE
    JAMA Surg; 2016 Apr; 151(4):347-54. PubMed ID: 26629783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Present and future of cancer biomarkers.
    Diamandis EP
    Clin Chem Lab Med; 2014 Jun; 52(6):791-4. PubMed ID: 24803613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive and prognostic cancer biomarkers revisited.
    Pritzker KP
    Expert Rev Mol Diagn; 2015; 15(8):971-4. PubMed ID: 26134385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
    Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
    Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
    Wei CC; Nie FQ; Jiang LL; Chen QN; Chen ZY; Chen X; Pan X; Liu ZL; Lu BB; Wang ZX
    Oncotarget; 2017 Jan; 8(3):5233-5246. PubMed ID: 28029651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.
    Jiang T; Xu X; Qiao M; Li X; Zhao C; Zhou F; Gao G; Wu F; Chen X; Su C; Ren S; Zhai C; Zhou C
    BMC Cancer; 2018 Mar; 18(1):267. PubMed ID: 29514610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential.
    Welch JD; Baran-Gale J; Perou CM; Sethupathy P; Prins JF
    BMC Genomics; 2015 Feb; 16(1):113. PubMed ID: 25765044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review.
    Bibault JE; Fumagalli I; Ferté C; Chargari C; Soria JC; Deutsch E
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):479-92. PubMed ID: 23595306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNAs as potential biomarkers in cancer: opportunities and challenges.
    Lan H; Lu H; Wang X; Jin H
    Biomed Res Int; 2015; 2015():125094. PubMed ID: 25874201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data.
    Li Y; Kang K; Krahn JM; Croutwater N; Lee K; Umbach DM; Li L
    BMC Genomics; 2017 Jul; 18(1):508. PubMed ID: 28673244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling exopeptidase activity from LC-MS data.
    Kluge B; Gambin A; Niemiro W
    J Comput Biol; 2009 Feb; 16(2):395-406. PubMed ID: 19193154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity.
    Balluff B; Hanselmann M; Heeren RM
    Adv Cancer Res; 2017; 134():201-230. PubMed ID: 28110651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [MUC4 research progress in tumor molecular markers].
    Zhu H; You J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Feb; 31(1):233-6. PubMed ID: 24804517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms.
    Leopoldino AM; Carregaro F; Silva CH; Feitosa O; Mancini UM; Freitas JM; Tajara EH
    Genome; 2007 May; 50(5):451-62. PubMed ID: 17612614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm.
    Martinez-Ledesma E; Verhaak RG; Treviño V
    Sci Rep; 2015 Jul; 5():11966. PubMed ID: 26202601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.